Market Research Report
Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Movement Disorders
|Published by||BCC Research||Product code||251478|
|Published||Content info||172 Pages
|Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Movement Disorders|
|Published: September 28, 2012||Content info: 172 Pages||
The global market for treatments for syndromes of dementia and movement disorders was valued at $10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.
Treatments for movement disorders are expected to be worth $3.2 billion in 2012 and $4.8 billion in 2017, a CAGR of 8.3%.
Sales of Parkinson's drugs used to treat movement disorder syndromes are expected to have a value of $2.9 billion in 2012 and nearly $4.3 billion in 2017, a CAGR of 8.1%
BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global markets for treatments for syndromes of dementia and movement disorders. The key objective is to present a comprehensive analysis and the future direction of the market as it shapes drug and therapy development.
This report explores present and future strategies within the neurodegenerative disorder market, which includes treatments and therapies for progressive dementia, progressive dementia with other neurological abnormalities and movement disorders. Market gains, setbacks and needs are discussed in this report. Comparisons, usage and the advantages and disadvantages of different types of technologies, including small molecules and monoclonal antibodies, are also presented in this report.
A detailed analysis of the structure of the syndromes of dementia and movement disorder industry has been conducted. Revenues are broken down by neurodegenerative disease and primary clinical/pathological feature. Sales figures are estimated for the five-year period from 2012 through 2017.
Applications for syndromes of dementia and movement disorder treatments, or therapeutic technologies, are also discussed separately in the report, with an emphasis on small molecule and monoclonal antibodies technology. The report also covers significant patents and their allotment in each category.
Extensive research in the field of syndromes of dementia and movement disorders and company collaborations with research institutes have highlighted the importance of understanding the nature of these disorders. New technological developments are providing disease-modifying therapies for the late stages of the disorders. Collaborations between research institutes and pharmaceutical companies are on the rise as state-of-the-art technology is being explored to develop more efficient products and therapies.
R&D spending, along with increasing competition, patent expiries and new technologies are taking the market in a new direction. Global market revenues increased from 2009 to 2011 and are expected to continue to show growth over the forecast period as new advances, launches and collaborations continue to influence the market. This study looks at most of the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type of technology in light of the new technologies, growing competition and changing customer needs.
This study contributes to the areas of market growth in treatments for Alzheimer's disease, Lewy body dementia, Pick's disease, Huntington's disease, corticobasal ganglionic degeneration, Parkinson's disease, multiple system atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.
The scope of this study encompasses the neurodegenerative disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and Mexico.
BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors' technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC spoke with officials within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.
The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this study is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.
Some of her other reports with BCC include Reagents for Chromatography; Spectroscopy - An Enduring Market; Advanced Drug Delivery Systems - Technologies and Global Markets; Orthopedic Drugs, Implants and Devices - Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry - The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging - Global Markets; Chiral Technology - Global Markets; Autacoids and Related Drugs - Technologies and Global Markets; Contraceptives - Technologies and Global Markets; Liver Disease Treatments - The Global Market; Hormone Replacement Therapies and Other Hormone Therapies - Global Markets; Cardiovascular Medicine - Diagnostics, Drugs and Devices; and Cancer Therapies - Technologies and Global Markets.
The lead consultant on this project is Ms. Ruma Chakravarty, who holds a master's degree in biophysics. She has tremendous experience in market research, quality, process improvement and lean and six sigma concepts.